These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
496 related articles for article (PubMed ID: 20074952)
1. The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. Glanzman AM; Mazzone E; Main M; Pelliccioni M; Wood J; Swoboda KJ; Scott C; Pane M; Messina S; Bertini E; Mercuri E; Finkel RS Neuromuscul Disord; 2010 Mar; 20(3):155-61. PubMed ID: 20074952 [TBL] [Abstract][Full Text] [Related]
2. Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND). Glanzman AM; McDermott MP; Montes J; Martens WB; Flickinger J; Riley S; Quigley J; Dunaway S; O'Hagen J; Deng L; Chung WK; Tawil R; Darras BT; Yang M; Sproule D; De Vivo DC; Kaufmann P; Finkel RS; ; Pediatr Phys Ther; 2011; 23(4):322-6. PubMed ID: 22090068 [TBL] [Abstract][Full Text] [Related]
3. Motor Function Test Reliability During the NeuroNEXT Spinal Muscular Atrophy Infant Biomarker Study. Krosschell KJ; Bosch M; Nelson L; Duong T; Lowes LP; Alfano LN; Benjamin D; Carry TB; Devine G; Kelley C; Gadekan R; Malkus EC; Pasternak A; Provance-Orr S; Roemeiser-Logan L; Nicorici A; Trussell D; Young SD; Fetterman JR; Montes J; Powers PJ; Quinones R; Quigley J; Coffey CS; Yankey JW; Bartlett A; Kissel JT; Kolb SJ; J Neuromuscul Dis; 2018; 5(4):509-521. PubMed ID: 30223401 [TBL] [Abstract][Full Text] [Related]
4. Commentary on "Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)". Cech D; Biedry NL Pediatr Phys Ther; 2011; 23(4):327. PubMed ID: 22090069 [No Abstract] [Full Text] [Related]
5. The test of infant motor performance: reliability in spinal muscular atrophy type I. Finkel RS; Hynan LS; Glanzman AM; Owens H; Nelson L; Cone SR; Campbell SK; Iannaccone ST; Pediatr Phys Ther; 2008; 20(3):242-6. PubMed ID: 18703961 [TBL] [Abstract][Full Text] [Related]
6. Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls. Darras BT; Masson R; Mazurkiewicz-Bełdzińska M; Rose K; Xiong H; Zanoteli E; Baranello G; Bruno C; Vlodavets D; Wang Y; El-Khairi M; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Fontoura P; Servais L; N Engl J Med; 2021 Jul; 385(5):427-435. PubMed ID: 34320287 [TBL] [Abstract][Full Text] [Related]
7. Brazilian version of the CHOP INTEND scale: cross-cultural adaptation and validation. Alves RMR; Calado APM; Van Der Linden V; Bello MAFC; Andrade LB Arq Neuropsiquiatr; 2023 Sep; 81(9):816-824. PubMed ID: 37793404 [TBL] [Abstract][Full Text] [Related]
8. Use of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) in X-Linked Myotubular Myopathy: Content Validity and Psychometric Performance. Duong T; Harding G; Mannix S; Abel C; Phillips D; Alfano LN; Bönnemann CG; Lilien C; Lowes LP; Servais L; Warken-Madelung B; Nieto Bergman S; James ES; Noursalehi M; Prasad S; Rico S; Bilder DA J Neuromuscul Dis; 2021; 8(1):63-77. PubMed ID: 32925083 [TBL] [Abstract][Full Text] [Related]
9. Evaluator Training and Reliability for SMA Global Nusinersen Trials1. Glanzman AM; Mazzone ES; Young SD; Gee R; Rose K; Mayhew A; Nelson L; Yun C; Alexander K; Darras BT; Zolkipli-Cunningham Z; Tennekoon G; Day JW; Finkel RS; Mercuri E; De Vivo DC; Baldwin R; Bishop KM; Montes J J Neuromuscul Dis; 2018; 5(2):159-166. PubMed ID: 29865090 [TBL] [Abstract][Full Text] [Related]
10. Reliability and validity of the TIMPSI for infants with spinal muscular atrophy type I. Krosschell KJ; Maczulski JA; Scott C; King W; Hartman JT; Case LE; Viazzo-Trussell D; Wood J; Roman CA; Hecker E; Meffert M; Léveillé M; Kienitz K; Swoboda KJ; Pediatr Phys Ther; 2013; 25(2):140-8; discussion 149. PubMed ID: 23542189 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany. Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734 [TBL] [Abstract][Full Text] [Related]
12. Quantitative Motion Measurements Based on Markerless 3D Full-Body Tracking in Children with SMA Highly Correlate with Standardized Motor Assessments. Blaschek A; Hesse N; Warken B; Vill K; Well T; Hodek C; Heinen F; Müller-Felber W; Schroeder AS J Neuromuscul Dis; 2022; 9(1):121-128. PubMed ID: 34308910 [TBL] [Abstract][Full Text] [Related]
13. Onasemnogene Abeparvovec in Type 1 Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis. Pascual-Morena C; Cavero-Redondo I; Lucerón-Lucas-Torres M; Martínez-García I; Rodríguez-Gutiérrez E; Martínez-Vizcaíno V Hum Gene Ther; 2023 Feb; 34(3-4):129-138. PubMed ID: 36136906 [TBL] [Abstract][Full Text] [Related]
14. Type I SMA "new natural history": long-term data in nusinersen-treated patients. Pane M; Coratti G; Sansone VA; Messina S; Catteruccia M; Bruno C; Sframeli M; Albamonte E; Pedemonte M; D'Amico A; Bravetti C; Berti B; Palermo C; Leone D; Brigati G; Tacchetti P; Salmin F; De Sanctis R; Lucibello S; Pera MC; Piastra M; Genovese O; Bertini E; Vita G; Tiziano FD; Mercuri E; Ann Clin Transl Neurol; 2021 Mar; 8(3):548-557. PubMed ID: 33547876 [TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2. Iwayama H; Kawahara K; Takagi M; Numoto S; Azuma Y; Kurahashi H; Yasue Y; Kawajiri H; Yanase A; Ito T; Kimura S; Kumagai T; Okumura A Brain Dev; 2023 Feb; 45(2):110-116. PubMed ID: 36335004 [TBL] [Abstract][Full Text] [Related]
16. Feeding and Swallowing Problems in Infants with Spinal Muscular Atrophy Type 1: an Observational Study. van der Heul AMB; Cuppen I; Wadman RI; Asselman F; Schoenmakers MAGC; van de Woude DR; Gerrits E; van der Pol WL; van den Engel-Hoek L J Neuromuscul Dis; 2020; 7(3):323-330. PubMed ID: 32333596 [TBL] [Abstract][Full Text] [Related]
18. Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy. De Sanctis R; Pane M; Coratti G; Palermo C; Leone D; Pera MC; Abiusi E; Fiori S; Forcina N; Fanelli L; Lucibello S; Mazzone ES; Tiziano FD; Mercuri E Neuromuscul Disord; 2018 Jan; 28(1):24-28. PubMed ID: 29174525 [TBL] [Abstract][Full Text] [Related]
19. Longitudinal natural history of type I spinal muscular atrophy: a critical review. Mercuri E; Lucibello S; Perulli M; Coratti G; de Sanctis R; Pera MC; Pane M; Montes J; de Vivo DC; Darras BT; Kolb SJ; Finkel RS Orphanet J Rare Dis; 2020 Apr; 15(1):84. PubMed ID: 32248834 [TBL] [Abstract][Full Text] [Related]
20. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1. Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]